SONN
Sonnet BioTherapeutics Holdings, Inc. Common StockstockNYSE
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 51.02 | 2026-11-20 | +0.16% | 0.000 |
| 6M | 1.26 | 2025-12-02 | +3955.56% | 0.000 |
| 1Y | 4.55 | 2025-11-21 | +1023.08% | -986.574 |
| 2Y | 2.89 | 2024-11-21 | +1668.17% | — |
| 5Y | 1,438.98 | 2021-11-22 | -96.45% | -14.751 |
Sonnet BioTherapeutics Holdings, Inc. Common Stock (NYSE:SONN) stock price today is $51.10, and today's volume is 1,183,907. SONN is up 3955.556% today. The 30 day average volume is 1.10M. SONN market cap is $348.88M with 6.83M shares outstanding.